Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Radiotherapy and Immunotherapy for Advanced Triple-Negative Breast Cancer
NCT06735131Phase 2Recruiting
- Sponsor
- Sun Yat-sen University
- Start
- Dec 2024
- Primary completion
- Jul 2026
- Modality
- Immune Checkpoint Inhibitors, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of toripalimab in triple-negative breast cancer (TNBC), sponsored by Sun Yat-sen University. Started Dec 2024; status: recruiting.
02
Drugs
toripalimab
03
Conditions
triple-negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT06735131.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06735131.